Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms.

Pearson DA, Santos CW, Aman MG, Arnold LE, Casat CD, Mansour R, Lane DM, Loveland KA, Bukstein OG, Jerger SW, Factor P, Vanwoerden S, Perez E, Cleveland LA.

J Child Adolesc Psychopharmacol. 2013 Jun;23(5):337-51. doi: 10.1089/cap.2012.0096.

2.

High concordance of parent and teacher attention-deficit/hyperactivity disorder ratings in medicated and unmedicated children with autism spectrum disorders.

Pearson DA, Aman MG, Arnold LE, Lane DM, Loveland KA, Santos CW, Casat CD, Mansour R, Jerger SW, Ezzell S, Factor P, Vanwoerden S, Ye E, Narain P, Cleveland LA.

J Child Adolesc Psychopharmacol. 2012 Aug;22(4):284-91. doi: 10.1089/cap.2011.0067. Epub 2012 Jul 31.

3.

Substance use and schizophrenia: adverse correlates in the CATIE study sample.

Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RS, McEvoy JP, Stroup TS; CATIE Investigators.

Schizophr Res. 2011 Nov;132(2-3):177-82. doi: 10.1016/j.schres.2011.07.032. Epub 2011 Aug 26.

PMID:
21872443
4.

Assessment of safety and long-term outcomes of initial treatment with placebo in TADS.

Kennard BD, Silva SG, Mayes TL, Rohde P, Hughes JL, Vitiello B, Kratochvil CJ, Curry JF, Emslie GJ, Reinecke MA, March JS; TADS.

Am J Psychiatry. 2009 Mar;166(3):337-44. doi: 10.1176/appi.ajp.2008.08040487. Epub 2009 Jan 15.

5.

Extrapyramidal side-effects of antipsychotics in a randomised trial.

Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

Br J Psychiatry. 2008 Oct;193(4):279-88. doi: 10.1192/bjp.bp.108.050088.

6.

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.

Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA; CATIE investigators.

Br J Psychiatry. 2008 Jul;193(1):37-43. doi: 10.1192/bjp.bp.107.042630.

7.

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D; Atomoxetine/Methylphenidate Comparative Study Group.

Am J Psychiatry. 2008 Jun;165(6):721-30. doi: 10.1176/appi.ajp.2007.05091676. Epub 2008 Feb 15.

PMID:
18281409
8.

The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.

Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA; CATIE Investigators.

Schizophr Res. 2008 Mar;100(1-3):39-52. doi: 10.1016/j.schres.2007.11.034. Epub 2008 Jan 11.

PMID:
18191383
9.

Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.

Spencer TJ, Kratochvil CJ, Sangal RB, Saylor KE, Bailey CE, Dunn DW, Geller DA, Casat CD, Lipetz RS, Jain R, Newcorn JH, Ruff DD, Feldman PD, Furr AJ, Allen AJ.

J Child Adolesc Psychopharmacol. 2007 Oct;17(5):689-700.

PMID:
17979588
10.

Treatment for Adolescents with Depression Study (TADS): safety results.

Emslie G, Kratochvil C, Vitiello B, Silva S, Mayes T, McNulty S, Weller E, Waslick B, Casat C, Walkup J, Pathak S, Rohde P, Posner K, March J; Columbia Suicidality Classification Group; TADS Team.

J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1440-55.

11.

Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS).

Vitiello B, Rohde P, Silva S, Wells K, Casat C, Waslick B, Simons A, Reinecke M, Weller E, Kratochvil C, Walkup J, Pathak S, Robins M, March J; TADS Team.

J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1419-26.

PMID:
17135987
12.

Acute time to response in the Treatment for Adolescents with Depression Study (TADS).

Kratochvil C, Emslie G, Silva S, McNulty S, Walkup J, Curry J, Reinecke M, Vitiello B, Rohde P, Feeny N, Casat C, Pathak S, Weller E, May D, Mayes T, Robins M, March J; TADS Team.

J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1412-8.

PMID:
17135986
13.

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.

Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.

Arch Pediatr Adolesc Med. 2006 Jan;160(1):82-90.

PMID:
16389216
14.

Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.

Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF.

J Atten Disord. 2004 Oct;8(2):45-52.

PMID:
15801334
15.

A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.

Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK.

J Am Acad Child Adolesc Psychiatry. 2004 Nov;43(11):1406-14.

PMID:
15502600
16.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.

Pediatrics. 2004 Jul;114(1):e1-8.

PMID:
15231966
17.

Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response.

Pearson DA, Lane DM, Santos CW, Casat CD, Jerger SW, Loveland KA, Faria LP, Mansour R, Henderson JA, Payne CD, Roache JD, Lachar D, Cleveland LA.

J Am Acad Child Adolesc Psychiatry. 2004 Jun;43(6):686-98.

PMID:
15167085
18.

Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD.

Pearson DA, Santos CW, Casat CD, Lane DM, Jerger SW, Roache JD, Loveland KA, Lachar D, Faria LP, Payne CD, Cleveland LA.

J Am Acad Child Adolesc Psychiatry. 2004 Jun;43(6):677-85.

PMID:
15167084
19.

Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial.

Davidson JR, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, van Meter S.

Biol Psychiatry. 2003 Jan 15;53(2):188-91.

PMID:
12547477
20.

Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD.

Pearson DA, Santos CW, Roache JD, Casat CD, Loveland KA, Lachar D, Lane DM, Faria LP, Cleveland LA.

J Am Acad Child Adolesc Psychiatry. 2003 Feb;42(2):209-16.

PMID:
12544181

Supplemental Content

Loading ...
Support Center